GenVault Announces Formation of Scientific Advisory Board With Focus on Best Practices for Integrated Biosample Management

Key Appointments Include Doctors and Researchers From MD Anderson Cancer Center, Rutgers University's Department of Genetics, and the Arizona Cancer Center

San Diego, CA July 13, 2004 GenVault, the leader in integrated biosample management, today announced the formation of its Scientific Advisory Board with the initial appointments of Dr. Waun Ki Hong of the MD Anderson Cancer Center at the University of Texas, Dr. Jay A. Tischfield of Rutgers University's Department of Genetics, and Dr. David S. Alberts of the Arizona Cancer Center at the University of Arizona. The Scientific Advisory Board will play a key role in keeping the company closely connected with the scientific research community and providing the company with ongoing intelligence regarding the evolving needs of those managing biosample libraries and repositories. Michael Hogan, Ph.D., co-founder and Chief Scientific Officer of GenVault, will serve as Director of the company's Scientific Advisory Board.

"We are dedicated to forming a talented and knowledgeable Scientific Advisory Board with members who will provide different perspectives and valuable insight into developing technology that will benefit all laboratories utilizing biosamples," commented Dr. Mitch Eggers, CEO of GenVault.

"We are honored that researchers as gifted and experienced as Drs. Hong, Tischfield, and Alberts have agreed to share their wisdom and join us in our ongoing pursuit of developing best practices for integrated biosample management. We look forward to working closely with them, and other future members, to improve GenVault's offering and performance," he continued.

Dr. Hong added, "In gathering a group of researchers from leading institutions and laboratories across the country, GenVault is reinforcing their commitment to keep a pulse on the scientific research community and its needs in order to continuously develop and refine best practices for integrated biosample management. I welcome the opportunity to be part of the GenVault's Scientific Advisory Board and I look forward to contributing to the further development of their innovative solutions," he continued.

Waun Ki Hong, M.D., serves several prestigious roles at the University of Texas, MD Anderson Cancer Center. In addition to serving as a Professor of Medicine, he is currently Head of the Division of Cancer Medicine, Chairman of the Department of Thoracic/Head and Neck medical Oncology, and the Charles A. LeMaistre Distinguished Chair in Thoracic Oncology. From 2001 to 2002, Dr. Hong served as the President of the American Association for Cancer Research and is a leading expert on the biology of head and neck cancers. At the center of Dr. Hong's research has been the development of pioneering chemoprevention trials that halt the onset or prevention of cancer. Born in Korea, Hong earned his medical degree from Yon Sei University School of Medicine in Seoul, Korea.

Jay Tischfield, Ph.D., FACMG, is the Chair of the Department of Genetics at Rutgers University, where he is also a Duncan & Nancy MacMillan Professor of Genetics. At Rutgers, Dr. Tischfield directs one of the largest human genetics research programs in the world and manages the cell lines for four major

National Institute of Health (NIH) centers, including the NIMH Center for Collaborative Studies on Mental Disorders, the NIDA Center for Genetic Studies, the NIDDK Genetics Repository, and the NIAAA/COGA Genetics Repository. He is also a Professor of Pediatrics and Psychiatry at Robert Wood Johnson Medical School, the University of Medicine and Dentistry of New Jersey (UMDNJ). Dr. Tischfield currently serves on the Scientific Advisory Committee for the New York Cancer Project, the Scientific Advisory Board for the Genomic Institute of Singapore, the Internal Advisory Board of the Cancer Center of New Jersey, the Editorial Advisory Board of the Journal of Molecular Medicine, the Board of Directors of Serinus Biotechnology Inc., and is the Chairman of the Scientific Advisory Board for Motif Biosciences. Dr. Tischfield received his Ph.D. from Yale University.

David S. Alberts, M.D., is a Regents Professor of Medicine, Pharmacology, and Public Health and Director of Cancer Prevention and Control for the Arizona Cancer Center at the University of Arizona. He also serves as the Associate Dean for Research for the College of Medicine, University of Arizona. For the past 17 years, Dr. Alberts has also been the Principal Investigator of University-wide Skin and Colon Cancer Prevention Program Project grants funded by the National Cancer Institute (NCI). Since 1975, Dr. Alberts has been performing laboratory and clinical research relation to the clinical pharmacology of cytotoxic and caner preventative agents. He is the Associate Editor of Cancer Research and Senior Editor of Cancer Epidemiology. Dr. Alberts also serves on the Scientific Advisory Board of the NCI. He received his M.D. from the University of Virginia, Charlottesville, his internal medicine training at the University of Wisconsin and the University of Minnesota, and his clinical pharmacology and medical oncology training at the NCI and the University of California, San Francisco.

About GenVault

GenVault is the leader in integrated biosample management.The company currently provides integrated archiving and retrieval solutions for organizations managing DNA collections. GenVault aims to serve customers including medical centers, academic institutions, pharmaceutical companies, and law enforcement agencies. Future systems will also accommodate proteins and RNA to provide a comprehensive solution. As a scalable and reliable alternative to traditional freezer networks and DNA purification systems, GenVault's dry-state platform enables the extraction, preservation and recovery of DNA at room temperature. This novel sample management solution is configured for each customer's workflow and the planned growth of their biosample archive. From its GenPlate to its Dynamic Archive solution, GenVault is continuously developing and refining best practices for integrated biosample management.